Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil for alcohol withdrawal syndrome
ACTRN12617000039381Phase 3Recruiting
- Sponsor
- Go Medical Industries
- Start
- Feb 2016
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of flumazenil in alcohol withdrawal syndrome (AWS), sponsored by Go Medical Industries. Primary endpoint: Withdrawal symptom severity throughout alcohol detoxification. Started Feb 2016; status: recruiting.
02
Drugs
flumazenil
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on ACTRN12617000039381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000039381.